Zacks.com on MSN17d
Denali's ALS Study Fails to Meet Primary and Secondary EndpointsDenali Therapeutics Inc. DNLI announced disappointing top-line results from an analysis of Regimen G of the phase II/III HEALEY ALS Platform Trial on pipeline candidate DNL343. The HEALEY platform ...
Zacks.com on MSN3d
Denali Gains 26.6% in a Year: How Should You Play the Stock?Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...
Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B ...
BTIG analyst Thomas Shrader lowered the firm’s price target on Denali Therapeutics (DNLI) to $32 from $35 and keeps a Buy rating on the shares ...
DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the HEALEY trial.
Denali has two wholly-owned, late-stage development programs, DNL310 for Hunter syndrome and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). DNL310 or tividenofusp alfa is an ...
Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product ...
Jan. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS Platform Trial evaluating eIF2B ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback